Passage Bio, Inc.
PASG · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $200 | $0 | $719 |
| Gross Profit | $0 | -$200 | $0 | -$719 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,307 | $5,814 | $7,737 | $9,558 |
| G&A Expenses | $4,348 | $4,520 | $6,085 | $0 |
| SG&A Expenses | $4,348 | $4,520 | $6,085 | $3,993 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$200 | $2,637 | $0 |
| Operating Expenses | $8,655 | $10,134 | $16,459 | $13,551 |
| Operating Income | -$8,655 | -$10,334 | -$16,459 | -$14,270 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $906 | $949 | $1,054 | $1,545 |
| Pre-Tax Income | -$7,749 | -$9,385 | -$15,405 | -$12,725 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,749 | -$9,385 | -$15,405 | -$12,725 |
| % Margin | – | – | – | – |
| EPS | -2.45 | -2.96 | -4.96 | -4.1 |
| % Growth | 17.2% | 40.3% | -21% | – |
| EPS Diluted | -2.45 | -2.96 | -4.96 | -4.1 |
| Weighted Avg Shares Out | 3,169 | 3,169 | 3,106 | 3,103 |
| Weighted Avg Shares Out Dil | 3,169 | 3,169 | 3,106 | 3,103 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $700 | $800 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $310 | $200 | $201 | $719 |
| EBITDA | -$7,439 | -$9,185 | -$13,621 | -$12,306 |
| % Margin | – | – | – | – |